Technavio's latest report on the global Huntington's disease (HD) therapeutics market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170818005115/en/
Technavio has published a new report on the global Huntington's disease therapeutics market from 2017-2021. (Graphic: Business Wire)
The global HD therapeutics market is expected to grow at a CAGR of almost 15% during the forecast period. The global HD therapeutics market has remained unchanged for the past few decades mainly because of the lack of approved therapies for the treatment of disease. Xenazine was the first drug to receive the US FDA approval in August in 2008. Recently, in April 2017, Teva's AUSTEDO is the second drug to be approved in this area. The approval of AUSTEDO is expected to have a significant impact on the market growth.
Sapna Jha, a lead analyst from Technavio, specializing in research on central nervous system sector, says, "The prevalence rate of HD is equal in both males and females, and the disease affects humans of all ethnic and racial groups. The disease symptoms first appear in the mid-life, between the ages of 25-45 years. In some cases, the disease symptoms may appear as early as the age of two years in children."
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
The top three emerging trends driving the global HD therapeutics market according to Technavio research analysts are:
- Advances in biomedical sciences
- Focus on regenerative therapies for mental disorders
- Rising public interest toward mental health
Looking for more information on this market? Request a free sample report
Technavio's sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Advances in biomedical sciences
In the past few decades, the advancement in science and introduction of nanotechnologies in the global pharmaceutical market, have revolutionized the development of medicines. With better understanding of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy, thus producing disease modifying drugs.
"Bioinformatics employs the use of mathematical model to enhance the understanding of human systems. This technology involves the creation and maintenance of biological database, which includes blood profile, stem cells, DNA sequences and others," according to Sapna.
Focus on regenerative therapies for mental disorders
The use of regenerative therapies is an emerging treatment option for the treatment of mental disorders. These regenerative therapies help in the healing process by replacement or regeneration of the human cells, tissues or organs and thus help in establishing the normal function.
The various regenerative techniques include stem cell therapy, growth factor therapy, and the use of matrix such as fibrin, collagen, urinary bladder matrix, hyaluronic acid and others. Various companies engaged in the development of regenerative medicines for the treatment of CNS disorders are BrainCells, Fate Therapeutics, Aldagen, and iZumi Bio.
Rising public interest toward mental health
Depression is relatively common in patients suffering from HD. Therefore, the use of antidepressants such as selective serotonin reuptake inhibitors (SSRIs) is given immediately after diagnosis. SSRIs are used as a first-line therapy due to easy dosing and their safety profile in case of overdosing, and they also have low adverse effect.
The CDC gathers data on the effects of depression on individuals and assesses them. This helps it to come up with more effective countrywide community-based programs to assist individuals. The CDC uses the Behavioral Risk Factor Surveillance System questionnaire to track the health and risk behavior of individuals in the US annually.
The key vendors are as follows:
- F. Hoffmann-La Roche
- H. Lundbeck
- Prana Biotechnology
- Teva Pharmaceutical Industries
Browse Related Reports:
- Global Schizophrenia Therapeutics Market 2017-2021
- Global Dementia and Movement Disorder Treatment Market 2017-2021
- Global Alzheimer's Drugs Market 2017-2021
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170818005115/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
